Acute Coronary Syndrome News and Research

RSS

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

Immediate catheterization not always better for ACS patients

For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.

1 Sep 2009

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Intermediate dosages of otamixaban reduce acute coronary complications

30 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Research study concludes the difference in mortality between men and women depending on the type of ACS

A new study from NYU School of Medicine found that women may have a slightly higher risk of death than men in the thirty days following an acute coronary syndrome (ACS), but that these differences appear to be attributable to factors such as severity and type of ACS.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

The Society of Chest Pain Centers (www.SCPCP.org), an international non-profit organization focused on improving care for cardiac patients, announces a new grant program in an effort to support research that is likely to result in a substantive contribution to acute cardiovascular medicine.

26 Aug 2009

Women face higher risk of mortality rate following acute coronary syndromes

Women may have a slightly higher risk of death than men in the 30 days following an acute coronary syndrome (ACS; such as heart attack or unstable angina), but this difference appears attributable to factors such as severity and type of ACS, clinical differences and angiographic severity according to a study in the August 26 issue of JAMA.

26 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

In middle-aged women, visceral fat, more commonly called belly fat, is known to be a significant risk factor for cardiovascular disease, but what causes visceral fat to accumulate?

21 Aug 2009

Celera and Aurora to collaborate on cardiovascular genetics

Aurora Health Care, Wisconsin's largest health care provider, and Celera Corporation announced today that they have entered into an agreement to collaborate on the integration of genetic testing aimed at optimizing heart care for Aurora patients

6 Aug 2009

Emergency physicians should trust their judgment on chest pain symptoms

Their research suggests that emergency physicians should counsel with other physicians against discharge when they feel strongly about a patient for whom there is no compelling data, other than our evaluation and judgment, Chandra said.

4 Aug 2009

Heart attacks kill 10,000 Australians each year and many could be avoided

A new report by Access Economics has revealed that this year 80,000 Australians can expect to be treated in hospital for heart attacks or chest pain - at a cost to the economy of $18 billion and 10,000 people will die from a heart attack.

28 Jun 2009

Do omega-3 fatty acids prevent depression in coronary heart disease?

Depression is an established risk factor for the development of coronary heart disease (CHD) in healthy patients and for adverse cardiovascular outcomes in patients with existing CHD. Dietary factors resulting in lower levels of omega-3 fatty acids not only increase CHD risk, but may also be involved in the pathophysiology of depression.

9 Jun 2009

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

In order to better prevent blood clots, clopidogrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

22 Apr 2009

Research may lead to new ways to fight clot formation

When plaques coating blood vessel walls rupture and expose collagen, platelets spring into action to form a blood clot at the damaged site.

16 Apr 2009

Certain combined medications following heart attack may increase risk of death

Following an acute coronary syndrome such as a heart attack or unstable angina, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of the antiplatelet drug clopidogrel and aspirin have an increased risk of subsequent hospitalization for acute coronary syndrome or death, according to a study in the March 4 issue of JAMA, the Journal of the American Medical Association.

2 Apr 2009

Acute Coronary Syndrome News and Research

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

Immediate catheterization not always better for ACS patients

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Intermediate dosages of otamixaban reduce acute coronary complications

Initial results of the CURRENT-OASIS 7 clinical trial due for release

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Research study concludes the difference in mortality between men and women depending on the type of ACS

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

Women face higher risk of mortality rate following acute coronary syndromes

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

Celera and Aurora to collaborate on cardiovascular genetics

Emergency physicians should trust their judgment on chest pain symptoms

Heart attacks kill 10,000 Australians each year and many could be avoided

Do omega-3 fatty acids prevent depression in coronary heart disease?

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

Research may lead to new ways to fight clot formation

Certain combined medications following heart attack may increase risk of death

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News